Beta-2 Microglobulin in Multiple Myeloma

Significance of Beta-2 Microglobulin

Beta-2 microglobulin is a standard measure of tumor burden in multiple myeloma and is considered one of the most important prognostic parameters, according to the National Comprehensive Cancer Network 1
Elevated levels of beta-2 microglobulin reflect increased tumor mass and are associated with poorer outcomes, as reported by the Annals of Oncology 2
The level of beta-2 microglobulin is incorporated into the International Staging System (ISS) for multiple myeloma, where it is combined with serum albumin to create a prognostic index, as stated by the Annals of Oncology 2, 3

Beta-2 microglobulin measurement is part of the initial diagnostic workup recommended for all patients with suspected multiple myeloma, according to the National Comprehensive Cancer Network 1
The combination of beta-2 microglobulin with serum albumin in the International Prognostic Index provides more comprehensive risk stratification than either marker alone, as reported by the Annals of Oncology 4

Higher beta-2 microglobulin levels (>5.5 mg/L) are associated with advanced disease and poorer survival outcomes, as reported by the Annals of Oncology 2
When interpreting beta-2 microglobulin levels, it's essential to note that renal dysfunction can artificially elevate levels independent of tumor burden, as beta-2 microglobulin is cleared by the kidneys, according to the National Comprehensive Cancer Network 1

The level of beta-2 microglobulin helps determine the appropriate treatment approach for patients with multiple myeloma, as reported by the Annals of Oncology 2
Patients with higher beta-2 microglobulin levels may require more aggressive treatment strategies due to their higher risk disease, as stated by the Annals of Oncology 4